Pressure sore anemia: Response to erythropoietin

Anemia in patients with grade IV pressure sores is usually refractory to therapy with iron salts, and red cell transfusions are commonly required when reconstructive surgery is performed. The anemia is characterized by hypoferremia, reticulocytopenia, and normal-to-increased serum ferritin. Five patients with this anemia were treated with recombinant human erythropoietin (rHuEPO) in doses of 50 to 100U/kg, given subcutaneously three times per week. The hemoglobin increased in every patient; the mean (±SD) value at the initiation of treatment was 8.8 ± 1.0g/dL, and after a median of 4 weeks of therapy, it was 12.4 ± 1.6g/dL (p < .001). No adverse effects of treatment were observed. It is concluded that rHuEPO is a promising new agent for pressure sore anemia, but randomized, controlled clinical trials will be required to firmly establish its place in the management of patients with this type of anemia.